Journal of Drugs in Dermatology最新文献_第9页

Safety and Effectiveness of Poly-L-Lactic Acid (PLLA-SCA) for Improvement in the Appearance of Cellulite. 聚l -乳酸（pla - sca）改善脂肪团外观的安全性和有效性。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9997

Katie Beleznay, Shannon Humphrey, Charlotta Wolgast, Felipe Weinberg, Daniel Bråsäter, Inna Prygova

{"title":"Safety and Effectiveness of Poly-L-Lactic Acid (PLLA-SCA) for Improvement in the Appearance of Cellulite.","authors":"Katie Beleznay, Shannon Humphrey, Charlotta Wolgast, Felipe Weinberg, Daniel Bråsäter, Inna Prygova","doi":"10.36849/JDD.9997","DOIUrl":"10.36849/JDD.9997","url":null,"abstract":"Background: Cellulite is related to collagen and elastic tissue degeneration in the dermis and hypodermis. Sculptra® poly-L-lactic acid (PLLA-SCA™) is a regenerative injectable, inducing collagen and elastin production to help restore the skin’s inner structure.Objective: This 12-month study was conducted to evaluate the effectiveness and safety of PLLA-SCA for the improvement of the appearance of cellulite in the posterior thighs.Methods: Women with grade 2–4 cellulite severity on the Galderma Posterior Thigh Cellulite Scale (GTCS) were injected with PLLA-SCA in the posterior thighs (max 3 vials/thigh) at 1–3 treatment sessions, 4–6 weeks apart. Assessments included improvement in cellulite appearance on the Global Aesthetic Improvement Scale (GAIS), GTCS, skin laxity, subject satisfaction, and adverse events (AEs). The primary endpoint was investigator-assessed GAIS at month 9. Time to return to daily activities after each treatment, and pre-defined injection-site responses were collected in a subject diary.Results: At month 9, 28/29 subjects (97%) had GAIS improvement on both thighs. Overall improvement rates were high on GAIS (≥93% months 2–12) and GTCS (79–100% months 6–12), with improved skin laxity in all subjects at months 6–12. Most subjects were satisfied with thigh appearance (97%) and reported improved skin sagginess (93%) and firmness (97%) at month 12. No treatment-related AEs occurred, and diary events were mainly tolerable and transient, resolving within 1 to 2 weeks.Conclusion: Treatment with PLLA-SCA progressively improved cellulite appearance, reaching ≥93% at months 9 through 12. GTCS improvement rates and subject satisfaction were high. The treatment was well tolerated. &nbsp.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 7","pages":"649-654"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pigmented Basal Cell Carcinoma in Skin of Color: A Systematic Review of the Literature. 有色皮肤中的色素基底细胞癌：文献的系统回顾。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9342

Victoria S Humphrey, Adewunmi Adelaja, Balaji Jothishankar, Ramone F Williams

{"title":"Pigmented Basal Cell Carcinoma in Skin of Color: A Systematic Review of the Literature.","authors":"Victoria S Humphrey, Adewunmi Adelaja, Balaji Jothishankar, Ramone F Williams","doi":"10.36849/JDD.9342","DOIUrl":"10.36849/JDD.9342","url":null,"abstract":"Background: Though basal cell carcinoma (BCC) is most often studied in Fitzpatrick Skin Types (FST) I-III, BCC in skin of color (SOC) is characterized by unique clinical features and a propensity toward pigmentation. While cutaneous malignancy occurs with decreased frequency in FST IV - VI, the diagnosis is generally associated with disproportionately increased morbidity and mortality. Accordingly, it is increasingly vital for dermatologists to recognize clinical presentations of skin cancer in individuals with SOC to improve outcomes and mitigate gaps in care.Objective: We systematically reviewed the literature regarding pigmented basal cell carcinoma (pBCC) in individuals with SOC.Methods and materials: The keywords “pigmented basal cell carcinoma” and “pBCC” were independently combined with “Asian,” “Black,” “Hispanic,” “Latinx,” “skin of color,” and “SOC” to perform a PubMed/MEDLINE search.Results: Based on the selected search terms, 26 unique articles were identified. Of these, 16 articles met the inclusion criteria for full-text screening.Conclusion: Pigmented BCC is more common in those with SOC and can be clinically challenging to diagnose. As evidence suggests that pBCC confers a favorable prognosis, efforts to standardize reporting and formalize sub-classification should be considered. Furthermore, as the existing literature is primarily retrospective with small sample sizes, larger prospective studies would be valuable additions to the literature and aid in shedding light on disparate outcomes associated with cutaneous malignancy in skin of color.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 7","pages":"605-610"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Tolerability of a Topical Pigment-Correcting Serum in Melasma and Postinflammatory Hyperpigmentation. 局部色素纠正血清治疗黄褐斑和炎症后色素沉着的疗效和耐受性。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9644

Pearl Grimes, Shanaya Dias, Priscilla Huang, Tsing Cheng, Elizabeth Makino

{"title":"Efficacy and Tolerability of a Topical Pigment-Correcting Serum in Melasma and Postinflammatory Hyperpigmentation.","authors":"Pearl Grimes, Shanaya Dias, Priscilla Huang, Tsing Cheng, Elizabeth Makino","doi":"10.36849/JDD.9644","DOIUrl":"10.36849/JDD.9644","url":null,"abstract":"Background: Melasma and postinflammatory hyperpigmentation (PIH) are common disorders of hyperpigmentation of key aesthetic concern. This study assessed the efficacy and tolerability of a serum formulated with lotus sprout extract, tranexamic acid, and niacinamide (LTN serum) for the treatment of melasma and PIH secondary to acne.Methods: A 16-week, single-center, open-label study enrolled women (≥20 years of age) with mild to severe melasma or PIH. Participants applied LTN serum twice daily on the full face. Endpoints included assessments of overall hyperpigmentation, skin tone unevenness, and tactile roughness, modified Melasma Area Severity Index (mMASI), Mexameter measurements of melanin content in target lesions, Melasma Quality of Life Questionnaire (MelasQoL), participant self-assessment questionnaires, and tolerability.Results: Of 30 female participants (n=15 per group), 57% self-identified as Black or African American, and 70% had Fitzpatrick skin types (FST) IV–VI. At week 16, significant decreases versus baseline were observed in both groups for overall hyperpigmentation (37% and 31% for the melasma and PIH groups, respectively; P<0.009 for both groups), skin tone unevenness (38% and 33%; P<0.008), and tactile roughness (67% and 52%; P≤0.005). mMASI and MelasQoL scores were significantly improved starting at week 4, with continuing significant improvement through week 16 (P≤0.05 and P>0.005, respectively). Mean change in melanin content was −36.5 at week 16 (melasma and PIH groups combined; P<0.0003). All tolerability parameters remained below mild.Conclusions: The LTN serum is an effective treatment for improving melasma and PIH, particularly among participants with FST IV–VI. &nbsp.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 7","pages":"596-604"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Latin America Cutaneous Oncology Management (LACOM) II: A Practical Algorithm for Managing Skin Toxicities in Oncology Patients. 拉丁美洲皮肤肿瘤管理（LACOM） II：管理肿瘤患者皮肤毒性的实用算法。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9768

Daniel Alcalá Pérez, Anneke Andriessen, Vanja Adzovic, Sebastian Andreani, Herbert Cárdenas, Marcela Moreno, Daniel Motola Kuba, Julia Riganti, José Enrique Ollague, Alejandra Toquica, Mario Lacouture

{"title":"Latin America Cutaneous Oncology Management (LACOM) II: A Practical Algorithm for Managing Skin Toxicities in Oncology Patients.","authors":"Daniel Alcalá Pérez, Anneke Andriessen, Vanja Adzovic, Sebastian Andreani, Herbert Cárdenas, Marcela Moreno, Daniel Motola Kuba, Julia Riganti, José Enrique Ollague, Alejandra Toquica, Mario Lacouture","doi":"10.36849/JDD.9768","DOIUrl":"https://doi.org/10.36849/JDD.9768","url":null,"abstract":"Background: Anticancer treatments are associated with cutaneous adverse events (cAEs) that can severely impact patients' quality of life (QoL) and interfere with treatment outcomes. LACOM aims to support clinicians in preventing and managing cAEs to optimize patient outcomes.Methods: A panel of dermatologists, clinical oncologists, and radiation oncologists developed an evidence-based algorithm for the prevention and treatment of cancer treatment-related cAEs using a skincare regimen that includes hygiene, moisturization, sun protection, and camouflage products.Results: The LACOM II algorithm discusses patient education before cancer treatment, appropriate skincare, triage, and the importance of treating emerging cAEs with a multidisciplinary team.Conclusions: Integrating proactive education, safe and effective skincare, triage, and reaction-specific management of cAEs is essential to optimize the care of patients living with cancer. The LACOM II algorithm provides evidence- and opinion-based best-practice recommendations to support clinicians working with oncology patients throughout the continuum of care, achieving optimal outcomes and improving patients' QoL. &nbsp.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 7","pages":"621-628"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cutaneous Adverse Effects of Hormonal and HER2-Targeted Therapies in Breast Cancer Patients: A Case Series. 激素和her2靶向治疗在乳腺癌患者中的皮肤不良反应：一个病例系列。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9458

Lenique Kl Huggins, Jaya Manjunath, May Alorainy, Jonathan S Leventhal, Sandhya Deverapalli

引用次数: 0

Rethinking the Link Between Hair Relaxers and Uterine Cancer. 重新思考头发松弛剂和子宫癌之间的联系。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9682

Shaveonté Graham

引用次数: 0

Benzoyl Peroxide Use is Not Associated with an Increased Risk of Skin Cancer: Findings from a Multicenter TriNetX Cohort Study. 过氧化苯甲酰的使用与皮肤癌风险增加无关：来自多中心TriNetX队列研究的发现

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9381

Neal Gupta, Fariha Hanif, Maile Ray, Ashley Shayya, Sandra McGinnis, Jared Jagdeo

引用次数: 0

Moringa-Derived Formulations for Hair Growth, Hair Preservation, and Hair Loss: A Systematic Review. 辣木衍生的头发生长，头发保存和脱发配方：系统回顾。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9796

Julia Stolyar, Lucie Joerg, Jared Jagdeo

{"title":"Moringa-Derived Formulations for Hair Growth, Hair Preservation, and Hair Loss: A Systematic Review.","authors":"Julia Stolyar, Lucie Joerg, Jared Jagdeo","doi":"10.36849/JDD.9796","DOIUrl":"10.36849/JDD.9796","url":null,"abstract":"Background: Hair plays a central role in personal identity, societal interactions, and cultural expression. As a result, hair growth, preservation, and loss are common dermatologic concerns for many patients across age groups and sexes. Recent data support the potential role of Moringa-derived formulations in the management of hair-related outcomes, due to their bioactive properties.Methods: A systematic search of PubMed, Embase, Cochrane Library, and Lens.org was conducted on January 2, 2026, according to PRISMA guidelines, for studies evaluating Moringa species and Moringa-derived preparations for hair-related outcomes.Results: Out of the 448 screened publications, 5 studies met the inclusion criteria, comprising 4 in vivo animal studies and 1 case series.Conclusions: Moringa-derived formulations were associated with increased hair length and hair weight in animal models, as well as reduced hair shedding in human study participants. Randomized controlled trials are necessary to establish whether Moringa is a suitable candidate for the management of hair growth, hair preservation, and hair loss. &nbsp.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 7","pages":"644-648"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sun Exposure and Cancer Outcomes (Incidence, Treatment, Survivorship) in Outdoor Workers. 户外工作者的阳光照射与癌症预后（发病率、治疗、生存率）。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9473

Samantha Kalner, Irene Vergilis

{"title":"Sun Exposure and Cancer Outcomes (Incidence, Treatment, Survivorship) in Outdoor Workers.","authors":"Samantha Kalner, Irene Vergilis","doi":"10.36849/JDD.9473","DOIUrl":"10.36849/JDD.9473","url":null,"abstract":"Outdoor workers in the Western United States (US), such as farm laborers, landscapers, and construction crews, face daily sun exposure far above safe limits, often up to ten times more than indoor workers, placing them at high risk for non-melanoma skin cancers and melanoma. Yet, despite decades of evidence, US regulations still do not classify solar ultraviolet (UV) radiation as a workplace hazard. Existing protections, like California’s heat illness rules, address temperature but ignore cumulative UV burden. In contrast, countries such as Australia and Germany treat solar UV as an occupational carcinogen and require employers to provide protective clothing, shade, and worker education. In the US, prevention remains inconsistent, weakened by regulatory gaps, poor data on work-related skin cancers, and barriers such as limited sunscreen use and cultural norms. These shortcomings fall hardest on immigrant and low-wage workers, who often have the least access to protection and care. This population-level occupational health case analysis calls for urgent policy reform to recognize solar UV as a workplace hazard and adopt stronger protections to reduce preventable skin cancer disparities.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 7","pages":"641-643"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the Safety and Efficacy of Sirolimus Topical Gel 0.2% to Treat Acanthosis Nigricans. 0.2%西罗莫司外用凝胶治疗黑棘皮病的安全性和有效性评价。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9457

Kayla Zafar, Margaret Kabakova, David Bitterman, Lucie Joerg, Jared Jagdeo

{"title":"Evaluating the Safety and Efficacy of Sirolimus Topical Gel 0.2% to Treat Acanthosis Nigricans.","authors":"Kayla Zafar, Margaret Kabakova, David Bitterman, Lucie Joerg, Jared Jagdeo","doi":"10.36849/JDD.9457","DOIUrl":"10.36849/JDD.9457","url":null,"abstract":"Background: There are currently no FDA-approved pharmacologic treatments for acanthosis nigricans (AN), a common dermatologic condition characterized by hyperpigmented, velvety plaques. AN disproportionately affects individuals with skin of color and is often associated with insulin resistance and obesity. There is a need for effective, safe, and well-tolerated treatments for AN.Objective: To evaluate the safety and efficacy of sirolimus gel 0.2% in improving pigmentation, skin texture, and quality of life in patients with AN.Methods: In this investigator-initiated, single-center, 12-week phase 2 pilot study, five adults with AN on the posterior neck applied sirolimus gel 0.2% twice daily. Assessments were conducted at baseline and weeks 4, 8, and 12. Efficacy was evaluated using a narrowband reflectance spectrophotometer and colorimeter to assess Melanin Index (M-index), Acanthosis Nigricans Scoring Chart (ANSC), Dermatology Life Quality Index (DLQI), Patient and Investigator Global Evaluations (PGE and IGE), and Treatment Satisfaction Questionnaire for Medication (TSQM). Safety and tolerability were monitored.Results: At week 12, participants demonstrated a significant reduction in pigmentation, with a 19.7% ± 4.9% decrease in M-index (P=0.0037) and a 30.2% reduction in ANSC scores (P=0.0011). Improvements were observed as early as week 4. DLQI scores improved significantly from baseline (P=0.0086). No serious adverse events occurred; mild application-site dryness and erythema were the only reported side effects.Conclusion: Sirolimus gel 0.2% was safe and effective for AN, producing early improvements in pigmentation, texture, and patient-reported outcomes. Larger randomized controlled trials are warranted to validate these findings. &nbsp.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 7","pages":"615-620"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0